Sonoma Pharmaceuticals Statistics
Want to see SNOA full AI Analyst Report?
Sonoma Pharmaceuticals (SNOA) Stock Statistics & Valuation Metrics
Total Valuation
Sonoma Pharmaceuticals has a market cap or net worth of $5.46M. The enterprise value is $2.28M.
- Market Cap
- $5.46M
- Enterprise Value
- $2.28M
Share Statistics
Sonoma Pharmaceuticals has 4,788,425 shares outstanding. The number of shares has decreased by -2.65% in one year.
- Shares Outstanding
- 4,788,425
- Owned by Insiders
- 7.38%
- Owned by Institutions
- 1.55%
Financial Efficiency
Sonoma Pharmaceuticals’s return on equity (ROE) is -1.03 and return on invested capital (ROIC) is -24.05%.
- Return on Equity (ROE)
- -1.03
- Return on Assets (ROA)
- -0.23
- Return on Invested Capital (ROIC)
- -24.05%
- Return on Capital Employed (ROCE)
- -0.27
- Revenue Per Employee
- 1.95M
- Profits Per Employee
- -317.50K
- Employee Count
- 10
- Asset Turnover
- 1.40
- Inventory Turnover
- 3.32
Valuation Ratios
The current PE Ratio of Sonoma Pharmaceuticals is -1.36. Sonoma Pharmaceuticals’s PEG ratio is -0.01.
- PE Ratio
- -1.36
- PS Ratio
- 0.25
- PB Ratio
- 0.92
- Price to FCF
- -2.13
- Price to Operating Cash Flow
- -2.28
- PEG Ratio
- -0.01
Income Statement
In the last 12 months, Sonoma Pharmaceuticals had revenue of 19.53M and earned -3.17M in profits. Earnings per share was -1.89.
- Revenue
- 19.53M
- Gross Profit
- 7.42M
- Operating Income
- -2.46M
- Pretax Income
- -3.42M
- Net Income
- -3.17M
- EBITDA
- -2.32M
- Earnings Per Share (EPS)
- -1.89
Cash Flow
In the last 12 months, operating cash flow was -2.67M and capital expenditures -120,000, giving a free cash flow of -2.79M billion.
- Operating Cash Flow
- -2.67M
- Free Cash Flow
- -2.79M
- Free Cash Flow per Share
- -0.57
Dividends & Yields
Sonoma Pharmaceuticals pays an annual dividend of ―, resulting in a dividend yield of ―
- Dividend Per Share
- ―
- Dividend Yield
- ―
- Payout Ratio
- N/A
- Free Cash Flow Yield
- -46.95%
- Earnings Yield
- -29.50%
Stock Price Statistics
- Beta
- 2.06
- 52-Week Price Change
- -66.80%
- 50-Day Moving Average
- 1.22
- 200-Day Moving Average
- 1.62
- Relative Strength Index (RSI)
- 59.09
- Average Volume (3m)
- 59.23K
Important Dates
Sonoma Pharmaceuticals upcoming earnings date is Feb 16, 2027, TBA (Not Confirmed).
- Last Earnings Date
- Nov 10, 2026
- Next Earnings Date
- Feb 16, 2027
- Ex-Dividend Date
- ―
Financial Position
Sonoma Pharmaceuticals as a current ratio of 2.50, with Debt / Equity ratio of 27.21%
- Current Ratio
- 2.50
- Quick Ratio
- 1.75
- Debt to Market Cap
- 0.06
- Net Debt to EBITDA
- 0.67
- Interest Coverage Ratio
- 0.00
Taxes
In the past 12 months, Sonoma Pharmaceuticals has paid -244.00K in taxes.
- Income Tax
- -244.00K
- Effective Tax Rate
- 0.07
Enterprise Valuation
Sonoma Pharmaceuticals EV to EBITDA ratio is -2.20, with an EV/FCF ratio of -0.69.
- EV to Sales
- 0.08
- EV to EBITDA
- -2.20
- EV to Free Cash Flow
- -0.69
- EV to Operating Cash Flow
- -0.72
Balance Sheet
Sonoma Pharmaceuticals has $4.61M in cash and marketable securities with $602.00K in debt, giving a net cash position of $4.01M billion.
- Cash & Marketable Securities
- $4.61M
- Total Debt
- $602.00K
- Net Cash
- $4.01M
- Net Cash Per Share
- $0.84
- Tangible Book Value Per Share
- $1.35
Margins
Gross margin is 39.23%, with operating margin of -3.32%, and net profit margin of -7.65%.
- Gross Margin
- 39.23%
- Operating Margin
- -3.32%
- Pretax Margin
- -5.93%
- Net Profit Margin
- -7.65%
- EBITDA Margin
- -3.74%
- EBIT Margin
- -4.16%
Analyst Forecast
The average price target for Sonoma Pharmaceuticals is ―, which is 11.43% higher than the current price. The consensus rating is ―
- Price Target
- ―
- Price Target Upside
- ―
- Analyst Consensus
- ―
- Analyst Count
- ―
- Revenue Growth Forecast
- 38.69%
- EPS Growth Forecast
- 58.68%
Scores
- Smart Score
- ―
- AI Score
- 48
